Background: The contribution of behavioural changes to functional decline is yet to be explored in primary progressive aphasia (PPA). Objectives: (1) investigate functional changes in two PPA variants [semantic (svPPA) and non-fluent (nfvPPA)], at baseline and after 12 months; (2) investigate baseline differences in behavioural changes between groups, and (3) explore predictors of functional decline after a 12-month period. Methods: A longitudinal study involving 29 people with PPA (18 svPPA; 11 nfvPPA) seen annually in Sydney/Australia was conducted. A total of 114 functional and behavioural assessments were included for within-group (repeated-measures ANOVA; annual rate of change; multiple regression analyses) and between-group analyses (pairwise comparisons). Results: Functional profiles in svPPA and nfvPPA were similar in people with up to 5 years of disease duration. Behavioural changes were marked in svPPA patients (stereotypical behaviour and apathy) but did not predict annual rate of change of functional abilities; global cognitive scores at baseline did. Despite mild behavioural changes in nfvPPA (disinhibition, apathy), these were significant predictors of annual rate of functional change. Conclusions: The presentation and interplay of behavioural changes and functional disability differ in svPPA and nfvPPA. These varying factors should be taken into account when considering prognosis, disease management, and selection of outcome measures for interventions.

1.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, et al: Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-1014.
2.
Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ, Piguet O, Burrell JR, Rowe CC, Hodges JR: Subtypes of progressive aphasia: application of the international consensus criteria and validation using B-amyloid imaging. Brain 2011;134:3030-3043.
3.
Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, Weintraub S, Bigio EH: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63:709-719.
4.
Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
5.
Mesulam MM: Primary progressive aphasia. Ann Neurol 2001;49:425-432.
6.
Jang J, Cushing N, Clemson L, Hodges JR, Mioshi E: Activities of daily living in progressive non-fluent aphasia, logopenic progressive aphasia and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:354-360.
7.
Mioshi E, Hodges JR: Rate of change of functional abilities in frontotemporal dementia. Dement Geriatr Cogn Disord 2009;28:419-426.
8.
Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR: Clinical staging and disease progression in frontotemporal dementia. Neurology 2010;74:1591-1597.
9.
Mioshi E, Kipps CM, Dawson K, Mitchell J, Graham A, Hodges JR: Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 2007;68:2077-2084.
10.
Wicklund AH, Johnson N, Rademaker A, Weitner BB, Weintraub S: Profiles of decline in activities of daily living in non-Alzheimer dementia. Alzheimer Dis Assoc Disord 2007;21:8-13.
11.
Lovibond PF, Lovibond SH: The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995;33:335-343.
12.
Ng F, Trauer T, Dodd S, Callaly T, Campbell S, Berk M: The validity of the 21-item version of the Depression Anxiety Stress Scales as a routine clinical outcome measure. Acta Neuropsychiatr 2007;19:304-310.
13.
Gelinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: The Disability Assessment for Dementia. Am J Occup Ther 1999;53:471-481.
14.
Mioshi E, Hodges JR, Hornberger M: Neural correlates of activities of daily living in frontotemporal dementia. J Geriatr Psychiatry Neurol 2013;26:51-57.
15.
Wear HJ, Wedderburn CJ, Mioshi E, Williams-Gray CH, Mason SL, Barker RA, Hodges JR: The Cambridge Behavioural Inventory revised. Dement Neuropsychol 2008;2:102-107.
16.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
17.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR: The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078-1085.
18.
Leyton CE, Hornberger M, Mioshi E, Hodges JR: Application of the Addenbrooke's Cognitive Examination to diagnosis and monitoring of progressive primary aphasia. Dement Geriatr Cogn Disord 2010;29:504-509.
19.
Hodges JR, Patterson K: Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol 2007;6:1004-1014.
20.
Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.
21.
Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y: Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. PLoS One 2013;8:e73645.
22.
O'Connor CM, Ahmed S, Mioshi E: Functional disability in primary progressive aphasia. Aphasiology 2014;28:1131-1149.
23.
O'Connor CM, Clemson L, Brodaty H, Gitlin LN, Piguet O, Mioshi E: Enhancing caregivers' understanding of dementia and tailoring activities in frontotemporal dementia: two case studies. Disabil Rehabil 2016;38:704-714.
24.
O'Connor CM, Clemson L, Hornberger M, Leyton CE, Hodges JR, Piguet O, Mioshi E: Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. Neurol Clin Pract 2016, Epub ahead of print.
25.
Kumfor F, Landin-Romero R, Devenney E, Hutchings R, Grasso R, Hodges JR, Piguet O: On the right side? A longitudinal study of left- versus right-lateralized semantic dementia. Brain 2016;139:986-998.
26.
Kashibayashi T, Ikeda M, Komori K, Shinagawa S, Shimizu H, Toyota Y, Mori T, Ishikawa T, Fukuhara R, Ueno S, et al: Transition of distinctive symptoms of semantic dementia during longitudinal clinical observation. Demen Geriatr Cogn Disord 2010;29:224-232.
27.
Bozeat S, Gregory CA, Ralph MAL, Hodges JR: Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;69:178-186.
28.
Cathery-Goulart MT, Knibb JA, Patterson K, Hodges JR: Semantic dementia versus nonfluent progressive aphasia: neuropsychological characterization and differentiation. Alzheimer Dis Assoc Disord 2012;26:36-43.
29.
Hodges JR, Patterson K, Oxbury S, Funnell E: Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115:1783-1806.
30.
Marra C, Quaranta D, Zinno M, Misciagna S, Bizzarro A, Masullo C, Daniele A, Gainotti G: Clusters of cognitive and behavioural disorders clearly distinguish primary progressive aphasia from frontal lobe dementia, and Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:317-326.
31.
Nyatsanza S, Shetty T, Gregory C, Lough S, Dawson K, Hodges JR: A study of stereotypic behaviours in Alzheimer's disease and frontal and temporal variant frontotemporal dementia. J Neurol Neurosurg Psychiatry 2003;74:1398-1402.
32.
Rosen HJ, Allison SC, Ogar JM, Amici S, Rose K, Dronkers N, Miller BL, Gorno-Tempini ML: Behavioural features in semantic dementia vs other forms of progressive aphasias. Neurology 2006;67:1752-1756.
33.
Hsieh S, Leyton C, Caga J, Flanagan E, Kaizik C, O'Connor CM, Kiernan MC, Hodges JR, Piguet O, Mioshi E: The evolution of caregiver burden in frontotemporal dementia with and without amyotrophic lateral sclerosis. J Alzheimers Dis 2015;49:875-885.
34.
Rohrer JD, Ridgway GR, Crutch SJ, Hailstone J, Goll JC, Clarkson MJ, Mead S, Beck J, Mummery C, Ourselin S, et al: Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010;49:984-993.
35.
Kertesz A, Blair M, McMonagle P, Munoz DG: The diagnosis and course of frontotemporal dementia. Alzheimer Dis Assoc Disord 2007;21:155-163.
36.
Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG: The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996-2005.
37.
Kertesz A, Davidson W, Munoz DG: Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Dement Geriatr Cogn Disord 1999;10:46-49.
38.
Singh TD, Duffy JR, Strand EA, Machulda MM, Whitwell JL, Josephs KA: Neuropsychiatric symptoms in primary progressive aphasia and apraxia of speech. Dement Geriat Cogn Disord 2015;39:228-238.
39.
Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR: How common are behavioural changes in amyolateral sclerosis? Amyotroph Lateral Scler 2011;12:45-51.
40.
Desai AK, Grossberg GT, Sheth DN: Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs 2004;18:853-875.
41.
Mohs RC, Schmeidler J, Aryan M: Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000;19:1401-1409.
42.
Hsieh S, Hodges JR, Leyton CE, Mioshi E: Longitudinal changes in primary progressive aphasias: differences in cognitive and dementia staging measures. Dement Geriatr Cogn Disord 2012;34:135-141.
43.
Kertesz A, Martinez-Lage P, Davidson W, Munoz DG: The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55:1368-1375.
44.
Schneider A, Hommel G, Blettner M: Linear regression analysis - part 14 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2010;107:776-782.
45.
Wagmiller RL: A fixed effects approach to assessing bias in proxy reports. Int J Public Opin Res 2009;21:477-505.
46.
Jonas C, Schiffczyk C, Lahmeyer C, Mueller F, Riepe MW: Staging dementia using proxy-reported activities of daily living. Dement Geriatr Cogn Disord 2011;32:111-117.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.